In part three of our series, we analyzed the outcomes of terminated deals in terms of the products that advanced in the clinic or went on to be approved post-termination.
You may also be interested in...
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.